Director of Formulation Research and Development

Guangzhou DiQi Pharmaceuticals (referred to as DiQi) stands as a pioneering pharmaceutical High-tech Enterprise dedicated to the advancement of Long-acting Injections (microspheres, implants, in-situ gels), sustained/controlled release drug delivery systems, and biodegradable excipients. Recognized as leading a medical innovation technology platform，DiQi is honored to be a specialized and sophisticated enterprise that produces new and unique products, a Guangdong Postdoctoral Innovation Practice Base, a Guangdong Postgraduate Joint training Base, a Guangdong Engineering Technology Research Center of Quality Consistency Evaluation for Generic Drugs, and a marketing authorization holder (MAH).
In terms of innovative preparations, DiQi has forged a 505(b)(2) drug technology platform with independent intellectual property rights, and has also developed a series of innovative pipelines. Among them are the world's first “risperidone microspheres injection (4W)” (approved for clinical trials by China CDE and U.S. FDA), the world's first “multi-target analgesic” (approved for clinical trials by China CDE and U.S. FDA), and the world's first “Lenalidomide sustained-release tablets” (approved for clinical trials by U.S. FDA). Additionally, we have several long-acting injections (LAIs) and innovative sustained/controlled-release products progressing through formulation development or preclinical stages.
In terms of indications, DiQi places a strategic focus on diseases requiring long-term or lifelong medication, including mental illnesses, neuropathy, diabetes, cancer, and viral infections.
In terms of medicinal and medical excipients, DiQi has developed a series of polylactic acid and poly (lactide-glycolide acid) copolymers, including PLLA, PLGA9505, PLGA8515, PLGA7525, PLGA6535 and PLGA5050. These products bridge technological gaps in excipients for LAIs, supporting the development and industrialization not only in China but also in Europe, the U.S., Japan, and South Korea.
In terms of generic drugs, DiQi has successfully developed over 40 generic drugs, with four drugs approved by the U.S. FDA for marketing, eleven drugs receiving consistency evaluations for generic drugs and successfully launching, eighteen drugs passing bioequivalence testing, and eight drugs currently under review.
In terms of intellectual property layout, DiQi has applied for 98 invention patents since its establishment, and has obtained 60 domestic and international invention patent authorizations. Among these, 31 patents have been authorized in China, while 29 have been authorized in Europe, the U.S., Japan, and South Korea, showcasing our global footprint in innovation and intellectual property protection.